title: Lidocaine self-sacrificially improves the skin permeation of the acidic and poorly water-soluble drug etodolac via its transformation into an ionic liquid.
abstract: Poor transdermal penetration of active pharmaceutical ingredients (APIs) impairs both bioavailability and therapeutic benefits and is a major challenge in the development of transdermal drug delivery systems. Here, we transformed a poorly water-soluble drug, etodolac, into an ionic liquid in order to improve its hydrophobicity, hydrophilicity and skin permeability. The ionic liquid was prepared by mixing etodolac with lidocaine (1:1, mol/mol). Both the free drug and the transformed ionic liquid were characterized by differential scanning colorimetry (DSC), infrared spectroscopy (IR), and saturation concentration measurements. In addition, in vitro skin-permeation testing was carried out via an ionic liquid-containing patch (Etoreat patch). The lidocaine and etodolac in ionic liquid form led to a relatively lower melting point than either lidocaine or etodolac alone, and this improved the lipophilicity/hydrophilicity of etodolac. In vitro skin-permeation testing demonstrated that the Etoreat patch significantly increased the skin permeation of etodolac (9.3-fold) compared with an etodolac alone patch, although an Etoreat patch did not increase the skin permeation of lidocaine, which was consistent with the results when using a lidocaine alone patch. Lidocaine appeared to self-sacrificially improve the skin permeation of etodolac via its transformation into an ionic liquid. The data suggest that ionic liquids composed of approved drugs may substantially expand the formulation preparation method to meet the challenges of drugs which are characterized by poor rates of transdermal absorption.
authors.affiliation: MEDRx Co., Ltd, 431-7 Nishiyama, Higashikagawa-city, Kagawa 769-2712, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Miwa
authors.affiliation: MEDRx Co., Ltd, 431-7 Nishiyama, Higashikagawa-city, Kagawa 769-2712, Japan.
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Hamamoto
authors.affiliation: Institute of Biomedical Sciences, Tokushima University, 1-78-1 Sho-machi, Tokushima 770-8505, Japan. Electronic address: ishida@tokushima-u.ac.jp.
authors.forename: Tatsuhiro
authors.initials: T
authors.lastname: Ishida
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D002626:Chemistry, Pharmaceutical / Q000379:methods; D004337:Drug Carriers / Q000737:chemistry; D017308:Etodolac / Q000008:administration & dosage* / Q000737:chemistry*; D005260:Female; D057927:Hydrophobic and Hydrophilic Interactions; D052578:Ionic Liquids / Q000737:chemistry*; D007477:Ions / Q000737:chemistry; D008012:Lidocaine / Q000008:administration & dosage* / Q000737:chemistry*; D010539:Permeability; D012867:Skin / Q000378:metabolism*; D012869:Skin Absorption; D012995:Solubility; D013552:Swine; D057968:Transdermal Patch; D014867:Water / Q000737:chemistry*
chemical_list: D004337:Drug Carriers; D052578:Ionic Liquids; D007477:Ions; D014867:Water; D017308:Etodolac; D008012:Lidocaine
keywords: Etodolac; Ionic liquid; Poorly water soluble drug; Skin permeability; Topical delivery